Drug profile

The FDA adverse-event record for Imidacloprid + Permethrin

64 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Imidacloprid + Permethrin. See the species affected, top reactions, and outcomes below.

64
adverse-event reports
7.8%
death-coded share
Dog
most-reported species
15
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
64
Total Reports
5
Deaths Reported
7.8%
Death Rate

Active Ingredients

ImidaclopridPermethrin

Administration Routes

TopicalUnknownOralOther

Species Affected

Dog 58
Cat 6

Most Affected Breeds

Domestic Shorthair 6
Chihuahua 5
Crossbred Canine/dog 5
Retriever - Labrador 3
Terrier - Yorkshire 3
Shepherd Dog - German 3
Shepherd Dog - Australian 3
Dog (unknown) 3
Spaniel - Cocker American 2
Mixed (Dog) 2

Most Reported Reactions

Vomiting 15
Lack of efficacy (ectoparasite) - flea 13
Seizure NOS 6
Behavioural disorder NOS 6
Pruritus 6
Diarrhoea 6
Muscle tremor 4
Lethargy (see also Central nervous system depression in 'Neurological') 4
Other abnormal test result NOS 4
Skin lesion NOS 3
Anorexia 3
Death by euthanasia 3

Outcome Breakdown

Outcome Unknown
31 (48.4%)
Recovered/Normal
16 (25.0%)
Ongoing
11 (17.2%)
Euthanized
3 (4.7%)
Died
2 (3.1%)
Recovered with Sequela
1 (1.6%)

Imidacloprid + Permethrin Adverse Event Insights

64 reports name Imidacloprid + Permethrin; 5 recorded a death outcome (7.8% of reported events, not a population-level mortality rate). Active ingredients: Imidacloprid, Permethrin. Administration routes: Topical, Unknown, Oral, Other.

By species: Dog (58 reports), Cat (6 reports). By breed: Domestic Shorthair (6), Chihuahua (5), Crossbred Canine/dog (5).

Leading clinical signs: Vomiting (15), Lack of efficacy (ectoparasite) - flea (13), Seizure NOS (6), Behavioural disorder NOS (6). Outcome, 64 coded reports: Outcome Unknown leads at 48.4%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.